Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2018-09-11 Capital/Financing Update
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
Phylogica Recapitalisation 2 pages 67.9KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 12 September 2018 regarding a capital raise by Phylogica through a placement of shares. It details the amount to be raised, the use of funds, the structure of the placement in two tranches, and mentions shareholder approval for the second tranche. The content focuses on fundraising activities and capital structure changes. There are no financial statements or detailed financial performance data, so it is not an Annual Report or Interim Report. It is not a regulatory certification or voting result announcement. The document is clearly an update on financing activities, specifically a share placement and capital raise. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content support a high confidence in this classification.
2018-09-11 English
Reinstatement to Official Quotation 1 page 412.6KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from ASX regarding the reinstatement to official quotation of Phylogica Limited's securities following a capital raising announcement. It is brief (688 characters) and serves as a notice rather than a detailed report. It does not contain financial statements or detailed financial data. The content fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about trading status and compliance, not a full report or detailed capital update.
2018-09-11 English
Suspension from Official Quotation 3 pages 483.9KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Phylogica Limited regarding a voluntary suspension of trading of its securities on the ASX pending a capital raising announcement. It references a request for voluntary suspension and states the suspension is until an announcement about the capital raising is made. There are no financial statements, detailed financial data, or report contents included. The document is short (2447 characters) and serves as an announcement of a trading suspension related to capital raising, not the capital raising details themselves. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit other more specific categories like Capital/Financing Update (CAP) because it does not provide details of the financing, only the suspension pending such announcement.
2018-09-10 English
Update on Capital Raising 2 pages 69.4KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement titled 'Update on Capital Raising' dated 11 September 2018. It provides details about a current capital raising effort, including the price per share, the nature of the offer (excluded offer to professional investors), support from major shareholders, and the intended use of funds. There are no financial statements or detailed financial performance data included. The document is relatively short (3794 characters) and focuses on providing an update about financing activities rather than presenting a full financial report or earnings release. This fits the definition of a Capital/Financing Update (CAP).
2018-09-10 English
Trading Halt 3 pages 283.3KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Phylogica Limited dated 7 September 2018, requesting a trading halt pending an announcement regarding a proposed capital raising transaction. The text explicitly states the halt is requested under ASX Listing Rule 17.1 and that the halt will remain until the announcement is made. There is no financial data, report, or detailed analysis included. The document is short (2500 characters) and serves as a notification of a trading halt related to a capital raising, not the capital raising announcement itself or a financial report. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit other more specific categories like Capital/Financing Update (CAP) which would require details of the financing event itself.
2018-09-06 English
Preliminary Final Report 17 pages 292.9KB
Annual Report Classification · 95% confidence The document is titled 'Appendix 4E Preliminary Final Report Year ended 30 June 2018' and contains detailed financial statements including profit and loss, financial position, cash flows, and notes to the financial statements. It includes directors' commentary, operating results, corporate and operational highlights, and detailed financial data for the full fiscal year ending June 30, 2018. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. The presence of comprehensive financial statements and notes confirms it is a full annual report. Appendix 4E is a common Australian Securities Exchange (ASX) form used for preliminary final reports, which are equivalent to annual reports. Therefore, this document fits the definition of an Annual Report (10-K). FY 2018
2018-08-30 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.